In the entire MBC population, 84.9% (2640/3111), listed were HR+/HER2-, 12.1% (377/3111) were HR+/HER2+, 0.9% (29/3111) were HR-/HER2+, and 2.1% (65/3111) were HR-/HER2-, while 92.0% (2863/3111) had early disease and 8.0% (248/3111) had metastatic cancer. This evidence concerns the gene HR and metastatic malignant neoplasm.